Mian Paola, Allegaert Karel, Spriet Isabel, Tibboel Dick, Petrovic Mirko
Intensive Care and Department of Paediatric Surgery, Erasmus MC, Sophia Children's Hospital, Room NA-1723, Wytemaweg 80, Rotterdam, 3015 CN, The Netherlands.
Division of Neonatology, Department of Pediatrics, Erasmus MC, Sophia Children's Hospital, Rotterdam, The Netherlands.
Drugs Aging. 2018 Jul;35(7):603-624. doi: 10.1007/s40266-018-0559-x.
Paracetamol is the most commonly used analgesic in older people, and is mainly dosed according to empirical dosing guidelines. However, the pharmacokinetics and thereby the effects of paracetamol can be influenced by physiological changes occurring with ageing. To investigate the steps needed to reach more evidence-based paracetamol dosing regimens in older people, we applied the concepts used in the paediatric study decision tree. A search was performed to retrieve studies on paracetamol pharmacokinetics and safety in older people (> 60 years) or studies that performed a (sub) analysis of pharmacokinetics and/or safety in older people. Of 6088 articles identified, 259 articles were retained after title and abstract screening. Further abstract and full-text screening identified 27 studies, of which 20 described pharmacokinetics and seven safety. These studies revealed no changes in absorption with ageing. A decreased (3.9-22.9%) volume of distribution (V) in robust older subjects and a further decreased V (20.3%) in frail older compared with younger subjects was apparent. Like V, age and frailty decreased paracetamol clearance (29-45.7 and 37.5%) compared with younger subjects. Due to limited and heterogeneous evidence, it was difficult to draw firm and meaningful conclusions on changed risk for paracetamol safety in older people. This review is a first step towards bridging knowledge gaps to move to evidence-based paracetamol dosing in older subjects. Remaining knowledge gaps are safety when using therapeutic dosages, pharmacokinetics changes in frail older people, and to what extent changes in paracetamol pharmacokinetics should lead to a change in dosage in frail and robust older people.
对乙酰氨基酚是老年人最常用的镇痛药,主要根据经验性给药指南给药。然而,对乙酰氨基酚的药代动力学以及由此产生的效果会受到衰老过程中发生的生理变化的影响。为了研究在老年人中达成更基于证据的对乙酰氨基酚给药方案所需的步骤,我们应用了儿科研究决策树中使用的概念。进行了一项检索,以获取关于老年人(>60岁)对乙酰氨基酚药代动力学和安全性的研究,或对老年人药代动力学和/或安全性进行(亚)分析的研究。在识别出的6088篇文章中,经过标题和摘要筛选后保留了259篇文章。进一步的摘要和全文筛选确定了27项研究,其中20项描述了药代动力学,7项描述了安全性。这些研究表明衰老对吸收没有影响。与年轻受试者相比,健康老年受试者的分布容积(V)降低了(3.9 - 22.9%),而体弱老年受试者的V进一步降低了(20.3%)。与年轻受试者一样,年龄和体弱状态会使对乙酰氨基酚的清除率降低(分别为29 - 45.7%和37.5%)。由于证据有限且存在异质性,很难就老年人对乙酰氨基酚安全性风险的变化得出确凿且有意义的结论。本综述是填补知识空白、迈向基于证据的老年受试者对乙酰氨基酚给药的第一步。仍存在的知识空白包括使用治疗剂量时的安全性、体弱老年人的药代动力学变化,以及对乙酰氨基酚药代动力学变化在多大程度上应导致体弱和健康老年人的剂量改变。